QUÉBEC CITY, July 7, 2011
/PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ)
(the "Company") today announced that an abstract on its
anticancer compound, AEZS-108, has been accepted and will be
presented during a poster session at the upcoming European Society
of Medical Oncology Congress to be held September 23-27, 2011, at the Stockholm
International Fairs in Stockholm,
Sweden. AEZS-108, a targeted cytotoxic peptide conjugate, is
currently in a Phase 1/2 program in prostate and bladder cancer,
and has successfully completed Phase 2 trials in endometrial and
ovarian cancer.
| Abstract: |
"A Phase I/II Trial of AEZS-108 (AN-152) in Castration-and
Taxane-Resistant Prostate Cancer", S. V. Liu, A. V. Schally, T.
Dorff, S. Groshen, D. Hawes, D. Quinn, Y.C. Tai, N. L. Block, J.
Engel, and J. Pinski. |
| Presenter: |
Dr. Jacek Pinski, Associate Professor of Medicine at the Norris
Comprehensive Cancer Center of the University of Southern
California |
| Date and
time: |
Sunday, September 24, 2011, 2:00 p.m. (local time) |
| Venue: |
Stockholm International Fairs, Stockholm, Sweden |
About AEZS-108
AEZS-108 represents a new targeting concept in oncology using a
hybrid molecule composed of a synthetic peptide carrier and a
well-known chemotherapy agent, doxorubicin. Phase 2 studies for the
treatment of endometrial and ovarian cancer have been successfully
completed, and Phase 1/2 trials are being conducted in prostate and
bladder cancer. AEZS-108 is the first intravenous drug in a
clinical study that directs the chemotherapy agent specifically to
LHRH-receptor expressing tumors, resulting in more targeted
treatment with less damage to healthy tissue. AEZS-108 has been
granted orphan-drug designation by the FDA and orphan medicinal
product designation from the EMA for the treatment of ovarian
cancer. Aeterna Zentaris owns the worldwide rights to AEZS-108.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development
company currently investigating potential treatments for various
cancers including colorectal, multiple myeloma, endometrial,
ovarian, prostate and bladder cancer. The Company's innovative
approach of "personalized medicine" means tailoring treatments to a
patient's specific condition and to unmet medical needs. Aeterna
Zentaris' deep pipeline is drawn from its proprietary discovery
unit providing the Company with constant and long-term access to
state-of-the-art therapeutic options. For more information please
visit www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.